OncoLink is the first multimedia oncology information resource placed on the Internet. OncoLink's mission is consistent with that of the University of Pennsylvania Medical Center, and the Abramson Cancer Center of the University of Pennsylvania which has sanctioned its use and development. OncoLink is accessible worldwide to anyone with Internet access, and there is no charge for its use. OncoLink has been established with the following objectives:
Jun 16, 2011 - The U.S. Food and Drug Administration has approved the Inform Dual ISH test, a genetic test to determine whether women with breast cancer are human epidermal growth factor receptor 2-positive and therefore candidates for trastuzumab (Herceptin).